patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

carbamazepine ER

Marketedupdated 2mo ago

by Riconpharma LLC

Approved

community read0 votes

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 9 investigational indications.

indications

investigational

Epilepsy

all catalysts(100)

approval · 100

view all 100 catalysts →

News(0)

no news has mentioned this drug yet

brand

Carbamazepine

generic

carbamazepine

MOA

Mechanism of Action Tegretol has demonstrated anticonvulsant properties in rats and mice with electrically and chemically induced seizures. It appears to act by reducing polysynaptic responses and blocking the post-tetanic potentiation. Tegretol greatly reduces or abolishes pain induced by stimulation of the infraorbital nerve in cats and rats. It depresses thalamic potential and bulbar and polysynaptic reflexes, including the linguomandibular reflex in cats. Tegretol is chemically unrelated to other anticonvulsants or other drugs used to control the pain of trigeminal neuralgia. The mechanism of action remains unknown. The principal metabolite of Tegretol, carbamazepine-10,11-epoxide, has anticonvulsant activity as demonstrated in several in vivo animal models of seizures. Though clinical activity for the epoxide has been postulated, the significance of its activity with respect to the safety and efficacy of Tegretol has not been established.

indication

Complex Partial Seizure

phase

marketed

carbamazepine ER

indications

all catalysts(100)

News(0)

comments(0)

Patent cliff

patents (7)

Report a data issue

🐶 often sniffed alongside

Trials studying carbamazepine ER